Polymyxins and their novel derivatives

Current Opinion in Microbiology

Volumn 13, Issue 5, 2010, Pages 574-581

  Vaara, Martti ^a,b  

^a Technopolis   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CB 182804; CLARITHROMYCIN; COLISTIN; NAB 7061; NAB 739; NAB 740; NAB 741; NAB 752; POLYMYXIN B; POLYMYXIN DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL OUTER MEMBRANE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY TUBULE EPITHELIUM; NEPHROTOXICITY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 77957816982     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2010.09.002     Document Type: Review

References (66)

1. Chopra J., Schonfield C., Everett M., O'Neill A., Miller K., Wilcox K., Frère J.-M., Dawson M., Czaplewski L., Urleb U., Courvalin P. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis 2008, 8:133-139.
2. Arias C.A., Murray B.E. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. New Engl J Med 2009, 360:439-443.
3. Zawascki A.P., Goldani L.Z., Li J., Nation R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antibiot Chemother 2007, 60:1206-1215.
4. Landman D., Georgescu C., Martin D.A., Quale J. Polymyxins revisited. Clin Microbiol Rev 2008, 21:449-465.
5. Nation R.L., Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009, 22:535-543.
6. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev 2007, 6:29-40.
7. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
8. Livermore D. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009, 64(Suppl. 1):i29-i36.
9. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to Gram-negative bacteria. New Engl J Med 2010, 362:1804-1813.
10. Kumarasamy K.K., Toleman M.A., Walsh T., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske c.G., Irfan S., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, published online August 11, 2010. 10.1016/S1473-3099(10)70143-2.
11. Cornaglia G., Rossolini G.M. The emerging threat of acquired carbapenemases in Gram-negative bacteria. Clin Microbiol Infect 2010, 16:99-101.
12. Kim H.B., Park C.H., Kim C.J., Kim E.C., Jacoby G.A., Hooper D.C. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother 2009, 53:639-645.
13. Fritsche T.R., Castanheira M., Miller G.H., Jones R.N., Armstrong E.S. Detection of methyltransferases conferring high-level resistance to aminoglycosides in Enterobacteriaceae from Europe, North America, and Latin America. Antimicrob Agents Chemother 2008, 52:1843-1845.
14. Mushtaq S., Warner M., Zhang J.-C., Maharjan S., Doumith M., Woodford N., Livermore D. Activity of ACHN-490 and other aminoglycosides vs. carbapenem-resistant Enterobacteriaceae isolated in the United Kingdom. Clin Microbiol Infect 2010, 16(Suppl. 2):S85.
15. Blair J.M.A., Piddock L.J.V. Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update. Curr Opin Microbiol 2009, 12:512-519.
16. Papp-Wallace K.M., Bethel C.R., Distler A.M., Kasuboski C., Taracila M., Bonomo R.A. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob Agents Chemother 2010, 54:890-897.
17. Drawz S.M., Bonomo R.A. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 2010, 23:160-201.
18. Page M.G.P., Dantier C., Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob Agents Chemother 2010, 54:2291-2302.
19. Danner R.L., Joiner K.A., Rubin M., Paterson W.H., Johnson N., Ayers K.M., Parrillo J.E. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 1989, 33:1428-1434.
20. Li J., Nation R.L., Milne R.W., Turnidge J.D., Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005, 25:11-25.
21. Falagas M.E., Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10:R27.
22. Oliveira M.S., Prado G.V.B., Costa S.F., Grinbaum R.S., Levin A.S. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 2009, 65:431-434.
23. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992, 56:395-411.
24. Tsubery H., Ofek I., Cohen S., Fridkin M. The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: studies on polymyxin B nonapeptide. Biochemistry 2000, 39:11838-11844.
25. 7 receptor functions by polymyxin B: crucial role of the hydrophobic tail of the antibiotic molecule. Brit J Pharmacol 2007, 150:445-454.
26. Pastewski A.A., Caruso P., Parris A.R., Dizon R., Kopec R., Sharma S., Mayer S., Ghitan M., Chapnick E.K. Parenteral polymyxin B use in patients with multidrug-resistant Gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann Pharmacother 2008, 42:1177-1187.
27. Hartzell J.D., Neff R., Ake J., Howard R., Olson S., Paolino K., Vishnepolsky M., Weintrb A., Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728.
28. Falagas M.E., Rafailidis P.I. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 2009, 48:1729-1731.
29. Nagai J., Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokin 2004, 19:159-170.
30. Moestrup S.K., Cui S., Vorum H., Bregengård C., Bjorn S.E., Norris K., Glieman J., Christensen E.I. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995, 96:1404-1413.
31. Vaara M., Fox J., Loidl G., Siikanen O., Apajalahti J., Hansen F., Frimodt-Moeller N., Nagai J., Takano M., Vaara T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 2008, 52:3229-3236.
32. Zavascki A.P., Goldani L.Z., Cao G., Superti S.C., Lutz L., Barth A.L., Ramos F., Boniatti M.M., Nation R.L., Li J. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008, 47:1298-1304.
33. Vaara M., Siikanen O., Apajalahti J., Frimodt-Møller N., Vaara T. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampin and clarithromycin. J Antimicrob Chemother 2010, 65:942-945.
34. Vingsbo Lundberg C., Vaara T., Frimodt-Møller N., Vaara M. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J Antimicrob Chemother 2010, 65:981-985.
35. Vaara M., Siikanen O., Apajalahti J., Fox J., Frimodt-Moeller J., He H., Poydyal A., Li J., Nation R.L., Vaara T. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 2010, 54:3341-3346.
36. Tsubery H., Ofek I., Cohen S., Fridkin M. N-terminal modifications of polymyxin B nonapeptide and their effect on antibacterial activity. Peptides 2001, 22:1675-1681.
37. Ali F.E., Cao G., Poydal A., Vaara T., Nation R.L., Vaara M., Li J. Pharmacokinetics of novel antimicrobial cationic peptides NAB7061 and NAB739 in rats following intravenous administration. J Antimicrob Chemother 2009, 64:1067-1070.
38. Vaara M, Vaara T: U.S. Patent Application Publication US2008/0287345.
39. Vaara M., Viljanen P., Vaara T., Mäkelä P. An outer membrane-disorganizing peptide PMBN sensitizes E. coli strains to serum bactericidal action. J Immunol 1984, 132:2582-2589.
40. Rose F., Heuer K.U., Sibelius U., Hombach-Klonisch S., Kiss L., Seeger W., Grimminger F. Targeting lipopolysaccharides by the nontoxic polymyxin B nonapeptide sensitizes resistant Escherichia coli to the bactericidal effect of human neutrophils. J Infect Dis 2000, 182:191-199.
41. Tsubery H., Yaakov H., Cohen S., Giterman T., Matiyahou A., Fridkin M., Ofek I. Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for Gram-negative bacteria. Antimicrob Agents Chemother 2005, 49:3122-3128.
42. Vaara M. New approaches in peptide antibiotics. Curr Opin Pharmacol 2009, 9:571-576.
43. Vaara M., Vaara T., Sarvas M. Decreased binding of polymyxin by polymyxin-resistant mutants of Salmonella typhimurium. J Bacteriol 1979, 139:664-667.
44. Velkov T., Thompson P.E., Nation R.L., Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010, 53:1898-1916.
45. 3 to antimicrobial and lipopolysaccharide binding activity. Chem Pharm Bull 2009, 57:240-244.
46. Katsuma N., Sato Y., Ohki K., Okimura K., Ohnishi K., Sakura N. Development of des-fatty acyl-polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity. Chem Pharm Bull 2009, 57:332-336.
47. Urakawa H., Yamada K., Komagoe K., Ando S., Oku H., Katsu T., Matsuo I. Structure-activity relationships of bacterial outer-membrane permeabilizers based on polymyxin B heptapeptides. Bioorg Med Chem Lett 2010, 20:1771-1775.
48. KPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009, 63:427-437.
49. KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecyclin and/or colistin. Antimicrob Agents Chemother 2010, 54:526-529.
50. Falagas M.E., Maraki S., Karageorgepoulos D.E., Kastoris A.C., Mavromanolakis E., Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae to fosfomycin. Int J Antimicrob Agents 2010, 35:240-243.
51. Walkty A., DeCorby M., Nichol K., Karlowsky J.A., Hoban D.J., Zhanel G.G. In vitro activity of colistin (polymyxin E) against 3,480 isolates of Gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob Agents Chemother 2009, 53:4924-4926.
52. Vaara M., Vaara T., Jensen M., Helander I., Nurminen M., Rietschel E., Mäkelä P. Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium. FEBS Lett 1981, 129:145-149.
53. Helander I., Kilpeläinen I., Vaara M. Increased substitution of phosphate groups in lipopolysaccharides and lipid A of the polymyxin-resistant pmrA mutants of Salmonella typhimurium: a 31P-NMR study. Mol Microbiol 1994, 11:481-487.
54. Nummila K., Kilpeläinen I., Zähringer U., Vaara M., Helander I. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol Microbiol 1995, 16:271-278.
55. Helander I.M., Kato Y., Kilpeläinen I., Kostiainen R., Lindner B., Nummila K., Sugiyama T., Yokochi T. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. Eur J Biochem 1996, 237:272-278.
56. Ernst R.K., Yi E.C., Guo L., Lim K.B., Burns J.L., Hackett M., Miller S.I. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 1999, 286:1561-1565.
57. Moskowitz S.M., Ernst R.K., Miller S.I. PmrA, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004, 186:575-579.
58. Raetz C.R.H., Reynolds C.M., Trent M.S., Bishop R.E. Lipid A modification systems in Gram-negative bacteria. Annu Rev Biochem 2007, 76:295-329.
59. Gunn J.S. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol 2008, 16:284-290.
60. Lee J., Patel G., Huprikar S., Calfee D.P., Jenkins S.G. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. Antimicrob Agents Chemother 2009, 47:1611-1612.
61. Woodford N., Tierno P.M., Young K., Tysall L., Palepou M.F., Ward E., Painter R.E., Suber D.F., Shungu D., Silver L.L., et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A betalactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004, 48:4793-4799.
62. Vaara M. Increased outer membrane resistance to ethylenediamine tetraacetate and cations in novel lipid A mutants. J Bacteriol 1981, 148:426-434.
63. Froelich J.M., Tran K., Wall D. A pmrA constitutive mutant sensitizes Escherichia coli to deoxycholic acid. J Bacteriol 2006, 188:1180-1183.
64. Li J., Nation R.L., Owen R.J., Wong S., Spelman D., Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007, 45:594-598.
65. Murata T., Tseng W., Guina T., Miller S.I., Nikaido H. PhoPQ-mediated regulation produces a more robust permeability barrier in the outer membrane of Salmonella enterica Serovar Typhimurium. J Bacteriol 2007, 189:7213-7222.
66. Fernández-Reyes M., Rodriguez-Falcón M., Chiva C., Pachón J., Andreu D., Rivas L. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteonomics 2009, 9:1632-1645.